.After a few years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma crease, taking up the leading scientific research location at Sanofi.Quigley will definitely begin Sept. 30 as the French Big Pharma's primary clinical officer and worldwide chief of research, Sanofi told Ferocious Biotech in an emailed statement.Quigley is replacing Frank Nestle, M.D., who left Sanofi this spring season amid an international overhaul of the business's R&D system. Nestle, that invested 8 years along with the pharma, leapt over to Deerfield Monitoring, where he currently functions as a companion on the rehabs group as well as CEO of the agency's therapeutic exploration and progression functions.
Quigley is going to participate in Sanofi coming from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile. He is actually presently noted as the firm's founder, president and chief executive officer.Considering that August 2021, Quigley has worked as an endeavor partner at SV Health Investors, a medical care fund supervisor with current investments in biotechs like BioAge, Cerevance, Dualitas Therapies and Nimbus Therapeutics, to name a few. Quigley previously stored the best spot at Dualitas, a biotech that stays in secrecy, depending on to STAT.The soon-to-be Sanofi leader also formerly helmed Therini Bio, an immunotherapy biotech operating to build procedures for neurodegenerative ailments driven by general disorder.Prior to spending the last few years in biotech, Quigley possesses an also longer performance history in Big Pharma, most recently serving as Gilead's senior bad habit head of state of investigation biology up until the summer season of 2021. Before that, he appeared more than four years all over various management duties at Bristol Myers Squibb and also worked as a scientific director at Johnson & Johnson's Janssen arm before that.Sanofi pointed out Quigley's mission in his brand new task would certainly be to "maximize our chance of success with superior cooperations around our association as well as past, taking best-in-class innovation and also developing and also sourcing new industry-leading talent with a commitment to range," according to an internal memorandum acquired through STAT.